OncoMatch/Clinical Trials/NCT07097363
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Is NCT07097363 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for b-cell non-hodgkin lymphoma.
Treatment: Cyclophosphamide · Doxorubicin · Epcoritamab · Etoposide · Prednisone · Rituximab — This phase II trial tests the safety, best dose, and effectiveness of epcoritamab when given with etoposide, cyclophosphamide, vincristine, doxorubicin, prednisone and rituximab (EPOCH-R) for the treatment of patients with aggressive B-cell non-Hodgkin lymphoma. Epcoritamab is a bispecific antibody that can bind to two different antigens at the same time. Epcoritamab binds to CD3, a T-cell surface antigen, and CD20 (a tumor-associated antigen that is expressed on B-cells during most stages of B-cell development and is often overexpressed in B-cell cancers) and may interfere with the ability of cancer cells to grow and spread. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells. It may also lower the body's immune response. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's DNA and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. The EPOCH-R is administrated as the standard of care treatment. This may help the immune system kill cancer cells. Giving epcoritamab with EPOCH-R may be safe, tolerable, and effective in treating patients with aggressive B-cell non-Hodgkin lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Biomarker criteria
Allowed: MYC translocation
High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations
Allowed: BCL2 translocation
High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations
Allowed: BCL6 translocation
High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations
Allowed: EBV positive
Epstein Barr virus (EBV) + DLBCL, NOS
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy for lymphoma
Exception: 1 prior cycle of chemoimmunotherapy allowed; prior radiotherapy allowed if not used as measurable site; steroids for symptom control allowed as specified
Prior systemic treatment for lymphoma. Prior radiotherapy is allowed provided that this site is not used as a measurable site to assess response. A maximum of 1 cycle of chemoimmunotherapy is allowed if needed for urgent disease stabilization if patient had staging PET/CT and LVEF evaluation prior to chemoimmunotherapy
Cannot have received: systemic therapy for indolent lymphoma
Prior systemic therapy for indolent lymphoma
Cannot have received: organ transplantation
Prior organ transplantation
Lab requirements
Blood counts
ANC ≥ 1,000/μL except in cases of marrow infiltration by lymphoma; Platelets ≥ 75,000 / mcL except in cases of marrow infiltration by lymphoma or hypersplenism; Hemoglobin ≥ 8 g/dL except in cases of marrow infiltration by lymphoma without RBC transfusion within 14 days of first treatment
Kidney function
Measured or calculated creatinine clearance (or GFR) ≥ 45 mL/min
Liver function
Serum total bilirubin ≤ 1.5 X ULN (≤ 3.0 x ULN if Gilbert disease) OR direct bilirubin ≤ ULN for subjects with total bilirubin > 1.5 ULN; AST and ALT ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver involvement
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50% on MUGA or ECHO
LVEF ≥ 50% on cardiac MUGA or ECHO; ANC ≥ 1,000/μL except in cases of marrow infiltration by lymphoma; Platelets ≥ 75,000 / mcL except in cases of marrow infiltration by lymphoma or hypersplenism; Hemoglobin ≥ 8 g/dL except in cases of marrow infiltration by lymphoma without RBC transfusion within 14 days of first treatment; Creatinine clearance (or GFR) ≥ 45 mL/min; Serum total bilirubin ≤ 1.5 X ULN (≤ 3.0 x ULN if Gilbert disease) OR direct bilirubin ≤ ULN for subjects with total bilirubin > 1.5 ULN; AST and ALT ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver involvement
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fred Hutch/University of Washington Cancer Consortium · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07097363 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy for lymphoma, systemic therapy for indolent lymphoma, organ transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify